Finding MYCure

Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine "...

Full description

Saved in:
Bibliographic Details
Published inMolecular & cellular oncology Vol. 6; no. 5; p. e1618178
Main Authors Beaulieu, Marie-Eve, Soucek, Laura
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.01.2019
Taylor & Francis Group
Subjects
Author’s Views
mini-protein
MYC
NSCLC
OMOMYC
peptide therapeutic
NSCLC
MYC
OMOMYC
mini-protein
peptide therapeutic
Online AccessGet full text

Cover

Abstract Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine "Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy", we demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo using an Omomyc-based mini-protein.
AbstractList Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine “Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy”, we demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo using an Omomyc-based mini-protein.
Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine "Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy", we demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo using an Omomyc-based mini-protein.Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine "Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy", we demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo using an Omomyc-based mini-protein.
Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine "Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy", we demonstrate for the first time the feasibility of pharmacological MYC inhibition and using an Omomyc-based mini-protein.
Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine “Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy”, we demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo using an Omomyc-based mini-protein.
Author Beaulieu, Marie-Eve
Soucek, Laura
Author_xml – sequence: 1
  givenname: Marie-Eve
  orcidid: 0000-0001-5224-8436
  surname: Beaulieu
  fullname: Beaulieu, Marie-Eve
  organization: Peptomyc S.L., Edifici Cellex
– sequence: 2
  givenname: Laura
  orcidid: 0000-0002-4750-7971
  surname: Soucek
  fullname: Soucek, Laura
  email: lsoucek@vhio.net
  organization: Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31528695$$D View this record in MEDLINE/PubMed
BookMark eNqFkcFuFDEMhiNURMtS3gDEkcsuiTOZSYSEQCsKlYq4wIFT5EmcJdVsUpJZUN-eGXZbtRwgl1i2_8-W_8fsKOVEjD0TfCW45q9AdiCValfAhVmJVmjR6QfsZM4v58LRnfiYndZ6yTkXCjQI9YgdyzlsjTphT89i8jFtXnz6tt4VesIeBhwqnR7-Bft69v7L-uPy4vOH8_W7i6VTshmXEnrZkTLUhADSeI5KEnYUkCMHpXpoPPDeBG-8QJCtapQUTWsAhOuMlwt2vuf6jJf2qsQtlmubMdo_iVw2FssY3UC2MRp9H5TvlW_Iae056ab1JMnoIGFivdmzrnb9lryjNBYc7kHvV1L8bjf5p2072QpQE-DlAVDyjx3V0W5jdTQMmCjvqgUwkoOc34I9vzvrdsjNQacGtW9wJddaKNy2CG5n7-yNd3b2zh68m3Sv_9K5OOIY87xyHP6rfrtXxxRy2eKvXAZvR7wecgkFk4t1WvGfiN-zP68T
CitedBy_id crossref_primary_10_1021_acsmedchemlett_4c00220
crossref_primary_10_1016_j_addr_2021_114044
crossref_primary_10_1083_jcb_202103090
crossref_primary_10_3390_molecules28155658
crossref_primary_10_1158_2767_9764_CRC_21_0103
Cites_doi 10.1038/ncomms5972
10.1177/1947601910378024
10.1371/journal.pone.0032172
10.1016/j.coph.2019.03.014
10.1126/scitranslmed.aar5012
10.1101/gad.2038411
10.1038/sj.cdd.4401443
10.1101/gad.205542.112
10.3389/fcell.2017.00010
ContentType Journal Article
Copyright 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. 2019
2019 The Author(s). Published with license by Taylor & Francis Group, LLC. 2019 The Author(s)
Copyright_xml – notice: 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. 2019
– notice: 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. 2019 The Author(s)
DBID 0YH
AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.1080/23723556.2019.1618178
DatabaseName Taylor & Francis Open Access
CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 0YH
  name: Taylor & Francis Open Access
  url: https://www.tandfonline.com
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate M.-E. BEAULIEU AND L. SOUCEK
EISSN 2372-3556
ExternalDocumentID oai_doaj_org_article_498adbf5db5d4ec88d0e846de3e98f32
PMC6736125
31528695
10_1080_23723556_2019_1618178
1618178
Genre Author's View
Journal Article
GrantInformation_xml – fundername: Instituto de Salud Carlos III
  grantid: PI13/01705
  funderid: 10.13039/501100004587
– fundername: European Research Council
  grantid: 617473
  funderid: 10.13039/501100000781
– fundername: BBVA Foundation
  grantid: 67_2015
  funderid: 10.13039/100007406
– fundername: Worlwide Cancer Research
  grantid: 13-1182
– fundername: European Research Council
  grantid: 617473
– fundername: ; ;
  grantid: 617473
– fundername: ;
  grantid: 13-1182
– fundername: ; ;
  grantid: PI13/01705
– fundername: ; ;
  grantid: 67_2015
GroupedDBID 00X
0YH
30N
53G
ABCCY
ABDBF
ACENM
ACGFS
ACUHS
ADBBV
ADCVX
AEULN
AEXWM
AGYJP
AIJEM
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AOIJS
BABNJ
BLEHA
CCCUG
DEAQA
DGEBU
DIK
EBS
EJD
EUPTU
GTTXZ
H13
HYE
KYCEM
LJTGL
M4Z
M~E
O9-
OK1
RPM
TDBHL
TFL
TFW
TTHFI
AAYXX
CITATION
GROUPED_DOAJ
NPM
7X8
5PM
ID FETCH-LOGICAL-c534t-32b37e59e4ff239d0a53ea7efa0a0255b24d20b9fd9d1a23654531469221c79d3
IEDL.DBID 0YH
ISSN 2372-3556
IngestDate Wed Aug 27 01:22:49 EDT 2025
Thu Aug 21 18:33:54 EDT 2025
Thu Jul 10 22:05:10 EDT 2025
Sat May 31 02:11:25 EDT 2025
Tue Jul 01 00:54:57 EDT 2025
Thu Apr 24 23:02:53 EDT 2025
Wed Dec 25 09:07:57 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 5
Keywords NSCLC
MYC
OMOMYC
mini-protein
peptide therapeutic
Language English
License open-access: http://creativecommons.org/licenses/by-nc-nd/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c534t-32b37e59e4ff239d0a53ea7efa0a0255b24d20b9fd9d1a23654531469221c79d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-5224-8436
0000-0002-4750-7971
OpenAccessLink https://www.tandfonline.com/doi/abs/10.1080/23723556.2019.1618178
PMID 31528695
PQID 2293023333
PQPubID 23479
ParticipantIDs informaworld_taylorfrancis_310_1080_23723556_2019_1618178
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6736125
crossref_primary_10_1080_23723556_2019_1618178
doaj_primary_oai_doaj_org_article_498adbf5db5d4ec88d0e846de3e98f32
proquest_miscellaneous_2293023333
pubmed_primary_31528695
crossref_citationtrail_10_1080_23723556_2019_1618178
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-01-01
PublicationDateYYYYMMDD 2019-01-01
PublicationDate_xml – month: 01
  year: 2019
  text: 2019-01-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular & cellular oncology
PublicationTitleAlternate Mol Cell Oncol
PublicationYear 2019
Publisher Taylor & Francis
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Group
References Soucek L. (CIT0004) 2002; 62
CIT0010
CIT0001
CIT0003
CIT0002
CIT0005
CIT0007
CIT0006
CIT0009
CIT0008
References_xml – ident: CIT0005
  doi: 10.1038/ncomms5972
– volume: 62
  start-page: 3507
  issue: 12
  year: 2002
  ident: CIT0004
  publication-title: Cancer Res
– ident: CIT0002
  doi: 10.1177/1947601910378024
– ident: CIT0009
  doi: 10.1371/journal.pone.0032172
– ident: CIT0010
  doi: 10.1016/j.coph.2019.03.014
– ident: CIT0001
  doi: 10.1126/scitranslmed.aar5012
– ident: CIT0006
  doi: 10.1101/gad.2038411
– ident: CIT0007
  doi: 10.1038/sj.cdd.4401443
– ident: CIT0008
  doi: 10.1101/gad.205542.112
– ident: CIT0003
  doi: 10.3389/fcell.2017.00010
SSID ssj0001528215
Score 2.110946
Snippet Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
informaworld
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e1618178
SubjectTerms Author’s Views
mini-protein
MYC
NSCLC
OMOMYC
peptide therapeutic
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7iQTwovq0vVvBabfNok6OKiwjrSUFPIelMUJAq6-7_d9J2l64Ie7HHNoFkJs18k8x8w9gFmaiq8I5H30SlUkOZGhNcajIC-wA5aozZyKPH4v5ZPryol16prxgT1tIDt4K7kkY78EGBVyCx0hoyJJsJKNDoIJrdl2xez5lq84PJlcjVLGVHZ1dclJxsa4xKyM1lpInPY2m1njFqOPt_MZb-hTt_h0_27NFwi212QHJw3U5gm61gvcPWRt1V-S7bGL43CSuD0evtdIx77Hl493R7n3bFD9JKCTlJBfeiRGVQhsCFgcwpga7E4DIX_QBPouSZNwEM5I6LgqCQoG3PcJ5XpQGxz1brzxoP2cBhFSRobYAaSTC-ItRTecCyFAXkWcLkTAq26pjBY4GKD5t3BKIz4dkoPNsJL2GX825fLTXGsg43UcTzxpHZunlB-radvu0yfSfM9BVkJ83BRmirkFixZADnM21a-ovi1Yir8XP6bTmhHkIv9CTsoNXufJgiLqbCqISVC3pfmMfil_r9rWHqjkFzhCCP_mPix2w9zqU9_jlhq5PxFE8JEE38WbP2fwAjoAIv
  priority: 102
  providerName: Directory of Open Access Journals
Title Finding MYCure
URI https://www.tandfonline.com/doi/abs/10.1080/23723556.2019.1618178
https://www.ncbi.nlm.nih.gov/pubmed/31528695
https://www.proquest.com/docview/2293023333
https://pubmed.ncbi.nlm.nih.gov/PMC6736125
https://doaj.org/article/498adbf5db5d4ec88d0e846de3e98f32
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BkRAHEG_Co1okrimJH7F9hIrVCml7ohI9WXZmDJVQttrH_2ecx9KtQD2QQ6QktuTMjO1vxuPPAB94imqbGET2TXSpLJrSuRRKVzHYR6zJUt6NvDxrFufq63c9ZRNuxrTK7EOngSiiH6tz5w5xM2XEfRTSCJ4mc4JB7U4y43tt7F24J7K1sklXF4s_YRbNPkWtp707_6p9MCv15P03qEv_BkBv5lFem5jmj-HRiChnnwYTeAJ3qHsK95fjmvkzeDi_7HeuzJYXp7s1PYfz-Zdvp4tyPAWhbLVU21KKKA1pRyolIR1WQUsKhlKoQnYIIstUVNEldFgHIRvGRJLHPydE3RqH8gUcdauOXsEsUJsUWuuQCyl0sWX400YkY2SDdVWAmqTg25EiPJ9U8cvXI5PoJDyfhedH4RVwsq92NXBk3FbhcxbxvnCmuO5frNY__NhjvHI2YEwao0ZFrbVYEYMlJEnOJikKcNcV5Ld9hCMNx5F4eUsD3k_a9Nyd8hpJ6Gi123jB8IdhDF8FvBy0u2-mzMbUOF2AOdD7wX8cfukuf_aU3Tl7jqHk6_9o8xt4kB-H8M9bONqud_SOAdE2Hvcmz3dZnR33QYXf4RT_Yw
linkProvider Taylor & Francis
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxEB5BkaAHyrN0yytIXDfs-rG2j1ARBWhyaqVysvyECrRBYXPh19ezj5BEoB66x11b8qxnPN_Y428A3iYX5SprCMYmPGfSi1ypaHJVJLDvfRlkwNvIs3k1PWefL_jFxl0YTKvEGDp2RBHtWo3GjZvRQ0rcO0IFSX4SMwxKNUbK91LI23CHq0pgFQNazP_us_AUVJR8uLzzv95bbqll79_hLv0XAt1NpNzwTJMH4AaZuoSUH-NVY8fuzw7d482EfggHPXAdve807RHcCvVjuDvrj-afwP3JZXtBZjT7erJahqdwPvl4djLN-2ILueOUNTkllorAVWAxEqp8YTgNRoRoCoNxh01TRwqrole-NIRWCXrRtMwqQkonlKeHsFcv6nAEIxNcZF5K5VMj5pV1CWU564MQtPJlkQEb_rV2PRM5FsT4qcuesHSQVaOsupc1g_G626-OiuO6Dh9wIteNkUm7fbFYftO9YWqmpPE2cm-5Z8FJ6YuQMJkPNCgZKclAbaqBbtqNlNhVPdH0mgG8GXRGJ6vFoxhTh8XqtyYJZSW0lJ4MnnU6tB4mRZWtFM9AbGnXlhzbX-rL7y0zOCbpJcR6fIMxv4Z707PZqT79NP_yHPbxU7fj9AL2muUqvEwYrLGvWiO7Al1SITA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VVqo4AC3P8NxKXLMkfsT2EQqrFrqrHqgEJ8v22KUCZatt9sKvx85j6a5APTTHxJY88YznG3vmM8Db6KJcZQ1JsQnPmUSRKxVMrooI9hFLL32qRp7OqqMz9vkbH7IJr_q0yhRDh44ool2rk3FfYhgy4t4RKkh0kynBoFTjxPheCnkHdqpEHp6qOIrZ320WHmOKkg-1O__rveaVWvL-DerSfwHQzTzKa45p8gDsIFKXj_JzvGzs2P3eYHu8lcx7cL-HraP3nZ7tw5avH8LutD-YfwT3Jhdtecxo-v1wufCP4Wzy6evhUd5ftZA7TlmTU2Kp8Fx5FgKhCgvDqTfCB1OYFHXYOHGksCqgwtIQWkXgReMiqwgpnVBIn8B2Pa_9MxgZ7wJDKRXGRgyVdRFjOYteCFphWWTAhl-tXc9Dnq7D-KXLnq50kFUnWXUvawbjVbfLjojjpg4f0jyuGice7fbFfHGue7PUTEmDNnC0HJl3UmLhIyJDT72SgZIM1HUt0E27jRK6O080vWEAB4PK6Giz6SDG1H6-vNIkYqyIleKTwdNOhVbDpEljK8UzEGvKtSbH-pf64kfLC55S9CJefX6LMb-B3dOPE31yPPvyAu6mL91200vYbhZL_yoCsMa-bk3sD6YRH9Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Finding+MYCure&rft.jtitle=Molecular+%26+cellular+oncology&rft.au=Beaulieu%2C+Marie-Eve&rft.au=Soucek%2C+Laura&rft.date=2019-01-01&rft.issn=2372-3556&rft.eissn=2372-3556&rft.volume=6&rft.issue=5&rft.spage=e1618178&rft_id=info:doi/10.1080%2F23723556.2019.1618178&rft.externalDBID=n%2Fa&rft.externalDocID=10_1080_23723556_2019_1618178
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2372-3556&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2372-3556&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2372-3556&client=summon